Please read the attached announcement jointly issued by Opal and Formulytica of the proposed merger.
Formulytica will be participating in the Australian Association of Regulatory and Clinical Scientists (ARCS) 2023 Annual Conference. This event for the pharmaceutical, biotech, and medical technology sector is scheduled to take place from June 6th to June 8th at the International Convention Centre in Darling Harbour, Sydney.
The ARCS Annual Conference brings together industry professionals, consumers, patients, practitioners, researchers, and academia to facilitate education, information sharing, and networking. With a program featuring over 85 sessions and seven concurrent streams per day, the conference covers cutting-edge topics, vital regulatory changes, and emerging trends. Participants will have the opportunity to contribute to discussions that shape the industry’s future, while receiving the latest updates on regulatory and clinical guidance.
Formulytica’s presence at the conference will allow us to showcase our expertise in pharmaceutical formulation development, particularly in clinical trial supply and the creation of high quality, innovative clinical-ready formulations. Our company’s strong track record in supporting clients from early formulation development through manufacturing and product launch, with the support of patents, demonstrates the vital role we play in the early life cycle of prescription, over the counter, and personal care products.
The conference anticipates more than 1,500 delegates, including professionals from industry, academia, and government. We look forward to meeting many old and new faces at Formulytica’s booth.
Our team of formulation scientists are proud to be representing Formulytica at the upcoming 55th annual The Australian Society of Cosmetic Chemists Conference at Crown Convention Centre, Melbourne/Naarm. With this year’s theme, “From small steps to giant leaps: sustainability for a new world”, we look forward to learning about the latest insights in sustainable practices in the beauty industry, as we work together to develop products that are kind to the skin and kind to the planet.
If you are attending, please look out for our team, or contact them via the conference app.
Formulytica is pleased to announce that it has been granted a licence from the Victorian Department of Health enabling it to develop new clinical-ready pharmaceutical formulations containing the drugs psilocybin and MDMA (3,4-methylenedioxy-methamphetamine). This news comes following the recent decision by the Therapeutic Goods Administration (TGA) in Australia to change the classification of psilocybin and MDMA, allowing authorised psychiatrists to prescribe them under the Authorised Prescriber Scheme for certain mental illnesses.
From 1 July 2023, Psilocybin and MDMA will be classified as Schedule 8 poisons when prescribed by authorised psychiatrists for certain medical conditions. Previously, they were classified as Schedule 9 poisons, meaning they were prohibited from use except for research or analytical purposes.
The change in classification is based on growing evidence that psilocybin and MDMA may have therapeutic benefits for a range of mental health conditions, including treatment-resistant depression and post-traumatic stress disorder. Formulytica is excited about the potential for these drugs to improve the lives of people suffering from these conditions, and is committed to developing safe and effective formulations to support their use.
Formulytica specialises in developing innovative drug formulations and analytical methods that are essential for any new medicine entering clinical trials. Our team has a deep understanding of the importance of developing robust formulations and analytical methods to ensure the safety, efficacy, and quality of drug products. With our expertise in developing a wide variety of dosage forms, including topical, oral, and injectable, and our expertise in analytical method development and stability testing, we are well-positioned to support the development of new clinical-ready formulations of psilocybin and MDMA.
For more information about the scheduling of poisons in Australia, please refer to the TGA’s website. For enquiries, contact us here.
Formulytica (Melbourne, Australia) and Singapore Eye Research Institute (SERI; Singapore) are pleased to announce that an international (PCT) patent application was filed in Singapore in May 2021. An outcome of their collaborative research, the patent covers a new drug delivery technology with application for reduction of scarring following eye surgery. This comes after formulation development and in vitro and in vivo proof of concept studies successfully demonstrated the applicability of this formulation technology, which has potentially broad applicability across a range of other therapeutic areas. Further work is ongoing to refine the technology and proceed to pre-clinical safety studies and eventually Phase 1 clinical studies.
About Formulytica Pty Ltd
Formulytica is an Australian innovative technology developer and service provider specialising in topical and injectable formulation development. Formulytica’s services include new product development and it specializes in the analytical science of semi-solid formulations for topical application utilised in dermatology, pharmaceutical, cosmetic, veterinary and personal care products, such as skincare and haircare. Formulytica’s injectable parenteral expertise covers solution and lipid-based formulations, in biologics, as well as small organic molecules. For more information, please visit www.formulytica.com.
About SERI
Established in 1997, the Singapore Eye Research Institute (SERI) is Singapore’s national research institute for ophthalmic and vision research. It is the research arm of the Singapore National Eye Centre, and affiliated to the National University of Singapore and the Duke-NUS Medical School. In two decades, SERI has grown from a team of 5 to over 250 staff, encompassing clinician scientists, scientists, fellows, students, support staff, as well as more than 245 distinguished adjunct faculty members to become the largest eye research institute in the Asia-Pacific region. As of Mar 2021, SERI has published 4,353 peer-reviewed papers supported by S$346 million in competitive research grants. SERI has trained more than 210 current and past graduate students; and has been conferred over 714 national & international awards and 145 patents. SERI further undertakes eye research in collaboration with local & international medical centres and research institutions, which has ensured a high level of research competency & skills transfer. Notably, SERI’s research has translated to actual patient success stories & significant improvements in eye care delivery. Today, SERI is recognized as a pioneering center for high quality eye research in Asia, with breakthrough discoveries that has translated to significant paradigm shift in eye care delivery. For more information, please visit https://www.snec.com.sg/research-innovation/about-seri.
Formulytica has hosted 3 Monash University students for their industry internship. These students are from various backgrounds such as marketing, biomedical science and media communications.
As part of Formulytica’s mission and values, we encourage innovative collaborations to produce exemplary results. Although working on separate projects, our interns have been moving forward as a cohesive unit, all the while gaining experience and expanding their knowledge in their fields. We wish them the very best with their future studies and careers.
Our CEO, Dr Richard Buchta, joined with other international delegates at the Third Precision Medicine & Medical Care and Aging International Forum in Tianjin, China this week. The event, hosted by Beroni Group, had the theme of “Innovation Driving Development, Technology Leading Future”. Scientists, experts and scholars in the healthcare industry from China, America, Japan, Australia presented their latest scientific and technological achievements towards innovative therapies for cancer and aging.
Formulytica joined with the Australian Biomedical & Digital Health Showcase hosted by Austrade Taipei as part of the 2019 Taiwan Healthcare+ Expo. The event aims to promote Australian capabilities and build commercial biomedical partnerships between Australia and Taiwan and the region. Our CEO, Dr Richard Buchta, participated in site tours and B2B meetings, and met with a number of prospective new clients in the biotechnology and pharmaceutical industry to discuss their topical and injectable drug formulation needs.
Formulation is key to the success of any pharmaceutical product. Formulytica’s CEO Dr Richard Buchta will speak about what is required for successful formulation development, technical transfer and scale up, including a number of case studies. Richard is presenting along with a range of other experts at the upcoming 2019 Biotech Development Lab, “Formula for Success”, hosted by BioMelbourne Network at the Victorian Comprehensive Cancer Centre, 13 September. For more information, visit this link.
As part of Formulytica’s expanding offerings in injectable and topical formulation development services, we are pleased to announce that we have the capability to assist our clients in developing liposomal formulations.
Liposomes are small, spherical particles composed of one or more phospholipid bilayers. Due to their small size (typically ranging from 100 to 200 nm in diameter), liposomes are often referred to as nanomedicine or nanotechnology. The size and structure of liposomes can be controlled by their formulation composition, and their method of manufacture. Some of the advantages of liposomes as a drug delivery vehicle are their ability to improve the solubility and stability of poorly water soluble drugs, their ability to increase the therapeutic window and bioavailability of drugs, and their excellent safety profile and biocompatibility.
Please contact us for more information about our liposomal formulation development services.
